Europe’s biosimilar blind spot: many biologics losing exclusivity have no competitionadriana.polo2025-04-23T15:36:21+02:00April 23, 2025|Read More
Regulations, market shifts and the biosimilar void: what’s at stake?adriana.polo2025-04-23T15:36:58+02:00March 28, 2025|Read More
Why are biosimilars still met with hesitation—and how can we change that?adriana.polo2025-03-25T10:43:27+01:00March 25, 2025|Read More
The golden era of biosimilars: patent expiration wave and their impact on global healthcareadriana.polo2025-02-20T15:42:58+01:00February 20, 2025|Read More
Navigating global shifts: key takeaways from the 2025 J.P. Morgan Healthcare Conferenceadriana.polo2025-02-03T09:38:27+01:00February 3, 2025|Read More
The blueprint for successful CDMO partnershipsadriana.polo2024-12-23T13:03:15+01:00December 23, 2024|Read More
From lab to market: mAbxience’s approach to biopharmaceutical developmentadriana.polo2024-12-02T12:04:35+01:00December 2, 2024|Read More
Biosimilar production: challenges and strategiesadriana.polo2024-11-19T11:06:10+01:00November 19, 2024|Read More
The role of CDMOs in global healthcare advancementsadriana.polo2024-11-20T10:15:33+01:00November 8, 2024|Read More
Overcoming the complex regulatory challenges in biopharmaceuticalsadriana.polo2024-09-30T18:26:06+02:00September 30, 2024|Read More
